Nurix Reports Q3 Revenue of $673.1M and Net Income of $549.8M
Revenue was driven primarily by a $653.2 million license payment from the Roche collaboration. Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 3…
Story updates
10:31:43 AM UTC
SquawkNews
Nurix Therapeutics reported third-quarter 2026 results with revenue of $673.1M and net income of $549.8M, a substantial year—over—year swing driven primarily by license revenue recognition from Roche; diluted EPS was $4.73 for the quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing…
2 million license payment from its Roche collaboration. 1 billion as of August 3…